Replimune Group announced the grant of inducement equity awards to Chris Sarchi, the Company’s newly appointed Chief Commercial Officer. The inducement awards consist of a non-qualified stock option to purchase 82,500 shares of the Company’s common stock and restricted stock units representing 55,000 shares of the Company’s common stock. The option has an exercise of $27.20 per share, which is equal to the closing price of the Company’s common stock on the date of grant. The option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the remainder vesting monthly for three years thereafter. The restricted stock units vest in approximately four equal annual installments beginning on November 15, 2023 . The inducement awards were granted under the Company’s previously approved Employment Commencement Incentive Plan, and were approved by the compensation committee of the Company’s board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). While the inducement awards were granted outside of Replimune’s 2018 Equity Incentive Plan, the awards will have terms and conditions consistent with those set forth under the plan.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on REPL:
- Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Barclays views GSK acquisition interest as positive for oncology stocks
- Replimune Group to participate in a conference call with JPMorgan
- Replimune Group price target raised to $58 from $43 at Piper Sandler